Azenta, Inc. balance sheet
At the end of fiscal 2025, Azenta, Inc. had total assets of $2.06bn, total liabilities of $333m and shareholders' equity of $1.73bn. It held $280m in cash against $0 of debt: net cash of $280m.
Balance sheet
| Fiscal year | 2009Sept 2009 | 2010Sept 2010 | 2011Sept 2011 | 2012Sept 2012 | 2013Sept 2013 | 2014Sept 2014 | 2015Sept 2015 | 2016Sept 2016 | 2017Sept 2017 | 2018Sept 2018 | 2019Sept 2019 | 2020Sept 2020 | 2021Sept 2021 | 2022Sept 2022 | 2023Sept 2023 | 2024Sept 2024 | 2025Sept 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 60 | 60 | 59 | 55 | 83 | 94 | 81 | 85 | 102 | 198 | 257 | 251 | 227 | 658 | 649 | 280 | 280 | 190 |
| Receivables | — | 92 | 77 | 79 | 77 | 80 | 86 | 106 | 93 | 125 | 166 | 95 | 120 | 164 | 157 | 154 | 142 | 144 |
| Inventory | — | 116 | 108 | 103 | 94 | 94 | 101 | 93 | 73 | 97 | 99 | 37 | 60 | 86 | 128 | 71 | 75 | 79 |
| Total current assets | — | 327 | 321 | 347 | 355 | 374 | 356 | 299 | 352 | 564 | 647 | 649 | 777 | 2,459 | 1,419 | 833 | 708 | 681 |
| Goodwill | — | 48 | 85 | 88 | 98 | 110 | 121 | 176 | 207 | 256 | 441 | 453 | 469 | 219 | 675 | 691 | 702 | 547 |
| Total assets | — | 518 | 637 | 742 | 737 | 778 | 759 | 686 | 767 | 1,095 | 1,516 | 1,559 | 1,820 | 3,716 | 2,885 | 2,100 | 2,060 | 1,876 |
| Accounts payable | — | 66 | 40 | 29 | 35 | 34 | 45 | 41 | 49 | 45 | 59 | 26 | 42 | 39 | 36 | 33 | 38 | 39 |
| Deferred revenue (current) | — | 4 | 14 | 10 | 20 | 26 | 18 | 15 | 23 | 29 | 29 | 26 | 26 | 40 | 35 | 30 | 32 | 36 |
| Total current liabilities | — | 108 | 96 | 81 | 93 | 114 | 113 | 120 | 147 | 165 | 272 | 211 | 345 | 231 | 211 | 206 | 238 | 273 |
| Short-term debt | — | — | — | — | — | — | — | — | — | 2 | 1 | 1 | — | — | — | — | — | — |
| Long-term debt | — | — | — | — | — | — | — | — | — | 194 | 50 | 50 | 50 | — | — | — | — | — |
| Total debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 199 | 52 | 51 | 50 | — | 0 | 0 | 0 | 0 |
| Total liabilities | — | 129 | 118 | 93 | 104 | 135 | 127 | 132 | 159 | 377 | 377 | 346 | 494 | 353 | 351 | 332 | 333 | 366 |
| Shareholders' equity | 318 | 389 | 518 | 649 | 632 | 643 | 632 | 554 | 608 | 718 | 1,139 | 1,214 | 1,325 | 3,363 | 2,534 | 1,768 | 1,727 | 1,510 |
| Net debt (negative = net cash) | −60 | −60 | −59 | −55 | −83 | −94 | −81 | −85 | −102 | 1 | −205 | −200 | −177 | −658 | −649 | −280 | −280 | −190 |
| Shares outstanding | — | 65m | 66m | 66m | 67m | 67m | 68m | 69m | 70m | 71m | 72m | 74m | 74m | 75m | 58m | 46m | 46m | 44m |
| Quarter | 2024 Q4Sept 2024 | 2025 Q1Dec 2024 | 2025 Q2Mar 2025 | 2025 Q3Jun 2025 | 2025 Q4Sept 2025 | 2026 Q1Dec 2025 | 2026 Q2Mar 2026 | 2026 Q3Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Receivables | 154 | 152 | 147 | 125 | 142 | 142 | 131 | 144 |
| Inventory | 71 | 75 | 75 | 81 | 75 | 82 | 79 | 79 |
| Total current assets | 833 | 848 | 710 | 678 | 708 | 780 | 727 | 681 |
| Goodwill | 691 | 673 | 683 | 704 | 702 | 703 | 553 | 547 |
| Total assets | 2,100 | 2,043 | 2,034 | 2,019 | 2,060 | 2,074 | 1,904 | 1,876 |
| Accounts payable | 33 | 32 | 39 | 38 | 38 | 39 | 33 | 39 |
| Deferred revenue (current) | 30 | 41 | 42 | 38 | 32 | 33 | 39 | 36 |
| Total current liabilities | 206 | 203 | 221 | 246 | 238 | 267 | 257 | 273 |
| Total liabilities | 332 | 323 | 339 | 346 | 333 | 360 | 349 | 366 |
| Shareholders' equity | 1,768 | 1,720 | 1,695 | 1,673 | 1,727 | 1,715 | 1,555 | 1,510 |
| Shares outstanding | 46m | 46m | 46m | 46m | 46m | 46m | 46m | 44m |
Compare with peers
- 10x Genomics, Inc. balance sheet
- Veracyte, Inc. balance sheet
- Neogenomics Inc balance sheet
- Repligen Corp balance sheet
- Twist Bioscience Corp balance sheet
Head to head: AZTA vs TXGAZTA vs VCYTAZTA vs NEOAZTA vs RGEN
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies